Search tips
Search criteria 


Logo of yonseimjYonsei Medical Journal WebsiteThis ArticleAbout the JournalInformation for ContributorsManuscript Submission
Yonsei Med J. 2007 December 31; 48(6): 1015–1019.
Published online 2007 December 31. doi:  10.3349/ymj.2007.48.6.1015
PMCID: PMC2628192

A Relationship of Sex Hormone Levels and Erectile Dysfunction: Which Tests Should Be Done Routinely?



In this study, the relationship between sex hormone levels and erectile dysfunction (ED), as well as the necessity of routinely measuring sex hormone levels were evaluated.

Materials and Methods

This study included one hundred patients admitted to a urology clinic for sexual dysfunction. To determine the hormone levels, following the history (included IIEF-5 score) and physical examination, triple blood samples were collected at intervals of 15 minutes between 08:00 and 10:00 am. Total and free testosterone, prolactin, follicle stimulating hormone and luteinizing hormone levels were studied.


Mean age was 43 (23 - 80) years. IIEF-5 score was less than 21 [9.8 - 4.3 (3 - 19)] in all study groups. There was a statistically significant correlation between tT and FSH, as well as between LH and FSH in Pearson (r = - 0.513, p < 0.001, respectively) and also in Spearman tests (r = - 0.224, p = 0.042 and r = - 0.459, p < 0.001, respectively). However, there was no correlation between age and serum hormone levels (p > 0.05). Of the 100 patients, 18 (18%) had low tT, 77 (77%) had normal and 5 (5%) had high tT levels. No statistically significant correlation was found between decreased libido and tT levels (p > 0.05). Twelve (66.6%) of the 18 patients with low tT had normal libido.


Analyzing the medical history in detail and performing a thorough physical examination can reduce the need for excessive studies and consultations, and enables patients to save time and costs.

Keywords: Hormones, diagnostic tests, erectile dysfunction, measurement and libido


Erectile dysfunction is defined as the inability to achieve or maintain an erection required for satisfactory sexual intercourse. It is a pathology that affects men's happiness, self-esteem and popular relations and may also contribute to serious psychological problems.1,2 According to the Massachusetts Male Aging Study, the prevalence of ED of all degrees is approximately 52% in men between 40 and 70 years.3 As most of the men are reluctant to discuss ED, more than 70% of ED cases remain undiagnosed.4 For this reason, most of the urologists perform an extensive screening of the patients admitted to urology clinics for ED.

Testosterone helps regulate sexual function; it organizes the sexual drive and stimulates masculine behavior.5 Testosterone is secreted episodically from the testicular Leydig cells in response to luteinizing hormone pulses, showing a diurnal pattern with a peak level in the early morning and a nadir in the evening. The unbound or active portion of testosterone accounts for approximately 2% of the total body stores, while the remaining 98% is bound to plasma proteins, primarily albumin and testosterone-estradiol-binding globulin.6 This unbound or free testosterone, which is equal to 2%, is physiologically active, with its effects exerted in the target cell where it may be converted to a more potent androgen, dihydrotestosterone, by 5-alpha reductase. Many factors can alter the amount of plasma proteins and, thus, affect the amount of biologically active free testosterone.7 Insufficient testosterone levels lead to a decrease in the relaxation of smooth muscle of corpus cavernosum.8

These diverse contributing factors necessitate the careful analysis of several parameters for diagnosing ED in patients. However, when the realities of costs and time are taken into consideration, only a routine examination is usually performed. While many of the diagnostic tests struggle to reduce costs. It is imperative that the evaluation remains sensitive enough to identify individuals with treatable endocrinopathies.7 In this respect, in our study, the relationship between sex hormone levels and ED, and the necessity of measuring hormone levels routinely for ED were evaluated.


In this study, we evaluated 100 consecutive patients admitted to an andrology clinic for ED. Inclusion criteria were: being ≥ 18 years old, having a clinically diagnosed ED for the previous 6 months as evaluated by our institution and having a regular sexual life with a female partner. Patients with a history of previous pelvic surgery, pelvic irradiation, chronic neurological disease, hypogonadism, or excess alcohol consumption, as well as those who were on medication during the recruitment period were excluded from the study. All patients completed a detailed questionnaire, the validated Sexual Health Inventory for Men 5-item questionnaire, based on the International Index of Erectile Function questionnaire which covered all of the aspects of erectile dysfunction (IIEF-5).9,10 A physician examined all of the patients following the interview and requested the necessary tests be performed.

Following 10 hours without food, triple blood samples for hormone analyses were taken at 15-minute intervals between 8.00 and 10.00 AM.11 Serum samples were kept at - 70[degree celsius] after a separation by centrifuge. Total testosterone (tT), free testosterone (fT), prolactin (PL), follicle stimulating hormone (FSH), and luteinizing hormone (LH) levels were studied with chemiluminescent immunoassay (ACS: 180-Chiron) and competitive radio immunoassay-(DSL) techniques. Measuring pituitary gonadotropins, FSH and LH can provide reliable clues to assist the physician in determining whether it is primary or secondary hypogonadism.

Based on the status of their libido, patients were divided into two groups as the normal libido group (n = 58) and the decreased libido group (n = 42). Libido groups were compared with age groups using chi-square tests. In addition, again using the chi-square test, libido groups were compared with groups classified according to tT, fT and PL levels. An unpaired, two-sample t-test, one-way ANOVA, logistic regression analyses and Spearman and Pearson's correlation analyses were used to compare the differences among the groups.


Mean age was 43 (23 - 80) years. The questionnaire took about 5 minutes to complete. IIEF-5 score was less than 21 [9.8 ± 4.3 (3 - 19)] in all study groups, which is indicative of ED. The IIEF-5 score was 17 to 21 in 6 of the 100 men (6%), suggesting mild ED; 11 to 16 in 40 (40%), suggesting mild to moderate ED; 8 to 10 in 18 (18%), suggesting moderate ED, and 7 or less in 36 (36%), suggesting severe ED.

The mean tT, fT, PL, FSH and LH levels were 14.5 ± 7.0 nmol/L (8.4 - 28.7 nmol/L, normal range), 72.5 ± 46.5 pmol/L (30.1 - 189.8 pmol/L), 12.9 ± 10.1 µg/L (1.6 - 18 µg/L), 8.4 ± 10.9 IU/L (< 11 IU/L) and 6.2 ± 6 IU/L (0.5 - 6 IU/L), respectively. There was a statistically significant correlation between tT and FSH and also between LH and FSH in Pearson (r = - 0.513, p < 0.001, respectively) and also in Spearman tests (r = - 0.224, p = 0.042 and r = - 0.459, p < 0.001, respectively). However, there was no correlation between age and serum hormone levels (p > 0.05).

Table 1 lists the mean values for tT, fT, and PL, as well as the rate of decreased libido according to the age groups. When the patients were classified according to decreased libido, only PL levels had a significant correlation with decreased libido (Table 2). There was an association between decreased libido and PL levels also on logistic regression analysis (Not shown on the tables, p = 0.046).

Table 1
The Mean Values of tT, fT, PL and the Rate of Decreased Libido in According to Age Group
Table 2
Mean Values of Age, tT, fT, PL, FSH and LH in According to Status of Libido

Of the 100 patients, 18 (18%) had low tT, 77 (77%) had normal and 5 (5%) had high tT levels. We did not find a significant correlation between decreased libido and tT levels by Student's t-test (p > 0.05). In addition to the information concerning testicular atrophy from the patients' charts, the data from a questionnaire on libido were reviewed for those patients (n = 18) with low tT level. Since these patients had normal testicles on examination and normal fT and PL levels, they were not evaluated further. On the other hand, 12 (66.6%) of these 18 patients with low tT had normal libido. The percentage of patients who had low, normal and high hormone levels are shown on Table 3 with respect to decreased libido.

Table 3
The Percentages of Patients who had a Low, Normal and High Hormone Levels in According to Status of Libido

Serum PL levels were available in 93 of our 100 patients (91.2%) and were low in 1 (1.1%), normal in 76 (81.7%) and high in 16 (17.2%) patients. None of these patients with a high PL level had a pituitary pathology and 5 of these 16 patients had a low tT (31.3%).


Understanding the dynamics of endocrine changes in the normally aging male is important not only because of the important role hormones play in the maintenance of sexual characteristics and sexual activity, but also for the diagnosis and management of endocrine and metabolic diseases. Data concerning the influence of age on androgens are inconsistent. Several researchers have reported a decrease in free and total testosterone concentrations, whereas others have failed to find age-related changes in testosterone.3,12 Although tT seems to decline slightly with age, we could not find any statistically significant correlation between age groups and the values of tT and fT.

This decline with age is related to decreased Leydig cell mass, decreased testicular perfusion with relative hypoxia and alterations in pituitary-hypothalamic function.13 FSH and LH show an increase with age, but PL has not been studied well in men. Davidson et al and Deslypere et al found no correlation between male PL levels and age, while Vekemans and Robyn reported a slight rise in PRL in 55 to 65 year-old men compared to those 20 years younger.14-16 In this study there was no correlation between age and PL levels.

In hypogonadic men, impaired erection response to visual sexual stimulation prompts consideration of androgens as enhancing erection, but not absolutely necessary.17,18 In 1% of ED cases caused by endocrinological problems, investigating serum testosterone levels once is sufficient when paired with a detailed history and physical examination.19 Johnson and Jarrow found a low incidence of endocrinopathy (2.1%) and noted that decreased libido and/or testicular atrophy would predict this condition with 100% sensitivity.20 They recommended laboratory testing only in patients with decreased libido and/or testicular atrophy. Slag et al studied 187 impotent patients and found no correlation between libido and hypogonadism in 35, while testicular atrophy correlated only with primary hypogonadism.21 In our study group (n = 100), only 42 patients had decreased libido and none of them had any type of endocrinopathy. Moreover, most of these patients had normal values of tT (80.5%) and PL (76%).

Fahmy et al reported that it is very difficult to establish a correlation between ED and serum testosterone levels; and demonstrated that low serum tT levels (< 10 nmol/mL) indicate hypogonadism.18 In the Massachusetts Male Aging Study, testosterone levels were confirmed to decline with age and free testosterone was found to be more predictive than tT.12 It has been suggested that only the measurement of free testosterone is sufficient in ED, and it is not necessary to analyze other hormones.7 Buvat and Lemaire recommended measuring testosterone in all the men > 50 years and in only those men who are < 50 years old but having decreased libido and abnormal physical findings.22 But Ansong et al. found that routine serum tT and fT measurement were not sufficient for decreased libido and ED.13 However, we have found no significant correlation between ED and the values of tT and fT.

Although it seems more likely that decreased libido is a secondary phenomenon related to a defence mechanism in men with ED, in the present study, no statistically significant relation was found between ED and libido. PL levels were found to have a significant relation with decreased libido. Govier et al found a 16% incidence of hypogonadism and 57% of this group had neither decreased libido nor testicular atrophy.7

Baskin reviewed 600 patients and found a 3% incidence of hyperprolactinemia and 7 patients had pituitary tumors (6 with low testosterone).23 Foster et al. found a 3.9% incidence of hyperprolactinemia with 2 pituitary tumors.24 One patient with pituitary tumor had decreased libido and decreased serum testosterone, and 1 had decreased libido but normal serum testosterone. In practice, performing a history and physical examination in conjunction with measurement of testosterone may not be sufficient to diagnose hypogonadism or hyperprolactinemia in these patients.25 Moreover, testosterone levels are not always depressed in endocrinological diseases.18 As such, we suggest that PL should be measured only in patients having any clinical signs and manifestation of endocrinopathy, not in all patients who present to a urology clinic for ED.

Measurement of hormones should be delayed until after taking a detailed history and performing a thorough physical examination. When these findings were evaluated with respect to other studies in the literature, measuring fT and especially PL should provide adequate information.

Taking a detailed medical history and performing a thorough physical examination with history can decrease the need for excessive studies and consultations, saving patients time and unnecessary cost.


1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270:83–90. [PubMed]
2. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol. 1999;161:5–11. [PubMed]
3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61. [PubMed]
4. Althof SE, Corty EW, Levine SB, Levine F, Burnett AL, McVary K, et al. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology. 1999;53:793–799. [PubMed]
5. Tellaloğlu S, Kadioğlu A. Sexual dysfunction in men, In Series of Andrology. Istanbul: Nobel Medical Co; 2000. pp. 143–147.
6. McClure RD, Marshall G. Endocrinologic sexual dysfunction. In: Singer C, Weiner WJ, editors. Sexual Dysfunction: A Neuro-Medical Approach. Armonk, NY: Futura Publishing Co; 1994. pp. 245–273.
7. Govier FE, McClure RD, Kramer-Levien D. Endocrine screening for sexual dysfunction using free testosterone determinations. J Urol. 1996;156:405–408. [PubMed]
8. McClure RD. Endocrine evaluation and therapy of erectile dysfunction. Urol Clin North Am. 1988;15:53–64. [PubMed]
9. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–830. [PubMed]
10. Cappelleri JC, Siegel RL, Glasser DB, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile dysfunction and the sexual health inventory for men. Clin Ther. 2001;23:1707–1719. [PubMed]
11. de la Torre B, Sjöberg B, Hedman M, Bártfai G, Diczfalusy E. A study of the short-time variation and interrelationship of plasma hormone levels reflecting pituitary, adrenocortical and testicular function in fertile men. Int J Androl. 1981;4:532–545. [PubMed]
12. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016–1025. [PubMed]
13. Ansong KS, Punwaney RB. An assessment of the clinical relevance of serum testosterone level determination in the evaluation of men with low sexual drive. J Urol. 1999;162(3 Pt 1):719–721. [PubMed]
14. Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab. 1979;48:955–958. [PubMed]
15. Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab. 1984;59:955–962. [PubMed]
16. Vekemans M, Robyn C. Influence of age on serum prolactin levels in women and men. Br Med J. 1975;27:738–739. [PMC free article] [PubMed]
17. Korenman SG, Morely JF, Mooradian AG, Davis SS, Kaiser FE, Silver AJ, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab. 1990;71:963–969. [PubMed]
18. Fahmy AK, Mitra S, Blacklock AR, Desai KM. Is the measurement of serum testosterone routinely indicated in men with erectile dysfunction? BJU Int. 1999;84:482–484. [PubMed]
19. Kaiser FE, Viosca SP, Morley JE, Mooradian AD, Davis SS, Korenman SG. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc. 1988;36:511–519. [PubMed]
20. Johnson AR, 3rd, Jarow JP. Is routine endocrine testing of impotent men necessary? J Urol. 1992;147:1542–1544. [PubMed]
21. Slag MF, Morley JE, Elson MK, Trence DL, Nelson CJ, Nelson AE, et al. Impotence in medical clinic outpatients. JAMA. 1983;249:1736–1740. [PubMed]
22. Buvat J, Lemaire A. Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol. 1997;158:1764–1767. [PubMed]
23. Baskin HJ. Endocrinologic evaluation of impotence. South Med J. 1989;82:446–449. [PubMed]
24. Foster RS, Mulcahy JJ, Callaghan JT, Crabtree R, Brashear D. Role of serum prolactin determination in evaluation of impotent patient. Urology. 1990;36:499–501. [PubMed]
25. Zonszein J. Diagnosis and management of endocrine disorders of erectile dysfunction. Urol Clin North Am. 1995;22:789–802. [PubMed]

Articles from Yonsei Medical Journal are provided here courtesy of Yonsei University College of Medicine